Core Insights - Medtronic plc will participate in several upcoming investor conferences, showcasing its commitment to engaging with investors and stakeholders [1][2][3][4]. Group 1: Upcoming Conferences - Medtronic will attend the 2025 Wells Fargo Healthcare Conference on September 4, 2025, with CEO Geoff Martha and CFO Thierry Piéton participating [1]. - The company will also be present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, featuring CFO Thierry Piéton [2]. - On September 10, 2025, Medtronic will participate in the 2025 Deutsche Bank Healthcare Summit, with Greg Smith, EVP of enterprise operations, addressing questions [3]. - The BofA Global Research Global Healthcare Conference is scheduled for September 24, 2025, where CFO Thierry Piéton will again represent the company [4]. Group 2: Company Overview - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges [5]. - The company employs over 95,000 individuals across more than 150 countries and offers solutions for 70 health conditions, including cardiac devices and surgical robotics [5]. - Medtronic's mission is to alleviate pain, restore health, and extend life, emphasizing its commitment to innovative healthcare solutions [5].

Core Viewpoint - Medtronic plc has appointed John Groetelaars and Bill Jellison as independent directors to enhance its strategic focus and operational execution, following constructive engagement with Elliott Management [1][4][5] Group 1: Board Appointments and Committees - John Groetelaars and Bill Jellison have been appointed to the Board of Directors, effective immediately [1] - The Board has formed new Growth and Operating committees to improve strategic portfolio management and capital allocation, with CEO Geoff Martha serving as Chair [2][3] - Groetelaars and Jellison will also serve on one or both of the newly formed committees [2] Group 2: Strategic Focus and Growth Initiatives - The formation of the committees aims to align governance with management's focus on operational improvement and capital allocation [2] - The Growth Committee will guide evaluations of M&A opportunities, R&D investments, and potential divestitures, including the separation of the Diabetes business [6] - The Operating Committee will focus on optimizing operational performance and driving earnings acceleration [6] Group 3: Future Outlook and Investor Engagement - Medtronic plans to host an Investor Day in mid-2026 to discuss strategic priorities and financial algorithms [3] - The company is experiencing strong momentum with multiple growth drivers and plans to launch additional breakthrough therapies [3] - Elliott Management expresses confidence in Medtronic's potential for exceptional value creation through operational improvements and strategic clarity [5] Group 4: New Board Member Backgrounds - John Groetelaars has over 30 years of experience in the medical device sector, previously serving as interim CEO of Dentsply Sirona and CEO of Hillrom [8][9] - William Jellison is a former CFO of Stryker Corporation and has extensive experience in corporate finance within the medical technology industry [10][11]

Group 1 - Medtronic's board of directors approved a cash dividend of $0.71 per ordinary share for the second quarter of fiscal year 2026 [1] - This dividend declaration aligns with the company's previous announcement of a dividend increase made in May 2025 [1] - Medtronic has a strong track record, being a member of the S&P 500 Dividend Aristocrats index, having increased its annual dividend for 48 consecutive years [1] Group 2 - Medtronic is headquartered in Galway, Ireland, and is recognized as a leading global healthcare technology company [2] - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions with its technologies and therapies [2] - Medtronic's mission focuses on alleviating pain, restoring health, and extending life through innovative healthcare solutions [2]

Financial Results Announcement - Medtronic plc will report its financial results for the first quarter of fiscal year 2026 on August 19, 2025, following the end of the quarter on July 25, 2025 [1] - The company plans to announce results for the subsequent quarters on November 18, 2025, February 17, 2026, and May 20, 2026 [1] Company Overview - Medtronic is a leading global healthcare technology company headquartered in Galway, Ireland, with over 95,000 employees across more than 150 countries [2] - The company's mission is to alleviate pain, restore health, and extend life, addressing 70 health conditions through various technologies including cardiac devices, surgical robotics, and patient monitoring systems [2] - Medtronic aims to deliver innovative technologies that transform lives, impacting two people every second [2]

Core Insights - Medtronic plc has appointed Dr. Joon Lee, CEO of Emory Healthcare, as an independent director on its Board, effective June 18, 2025 [1] - Dr. Lee will contribute to the Science and Technology Committee and Compensation and Talent Committee [1] Company Overview - Medtronic is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [6] - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions with its technologies [6] Dr. Joon Lee's Background - Dr. Lee has over 25 years of experience at the University of Pittsburgh Medical Center (UPMC), where he held significant roles including Executive Vice President and President of Physician Services [3] - He has a strong background in cardiology, having served as Chief of the Division of Cardiology and founding executive director of the UPMC Heart and Vascular Institute [4] - Dr. Lee's educational credentials include a BA from Dartmouth College and an MD from Duke University, along with extensive training in cardiology at Massachusetts General Hospital [5] Financial and Operational Insights - Emory Healthcare, under Dr. Lee's leadership, generates $7.7 billion in annual revenue and operates 12 hospitals with over 29,000 employees [2] - Dr. Lee also served as Chief Medical Officer of UPMC Insurance Services, which is a $13 billion health insurance division [4] Strategic Vision - Dr. Lee is recognized for his commitment to leveraging data and technology to enhance patient and provider experiences, aligning with Medtronic's mission [2]

Core Viewpoint - Medtronic plc will participate in Bernstein's 41st Strategic Decisions Conference on May 29, 2025, where CEO Geoff Martha will present and answer questions alongside CFO Thierry Piéton [1][2]. Company Overview - Medtronic is a leading global healthcare technology company headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [4]. - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions through various technologies and therapies, including cardiac devices, surgical robotics, and patient monitoring systems [4]. - Medtronic aims to deliver innovative technologies that transform lives, impacting two people every second [4]. Event Details - The presentation by CEO Geoff Martha will begin at 11:00 a.m. EDT on May 29, 2025, followed by a Q&A session with CFO Thierry Piéton [2]. - A live webcast of the event will be available on Medtronic's investor relations website, with an archive accessible later the same day [3].

Core Insights - Medtronic plc will report its financial results for the fourth quarter and full fiscal year 2025 on May 21, 2025, with a news release at approximately 5:45 a.m. CDT [1] - A video webcast will be held at 7:00 a.m. CDT on the same day to discuss the financial results, with a replay and transcript available within 24 hours [2] - Looking ahead, Medtronic plans to report its quarterly results for fiscal year 2026 on August 19, November 18, February 17, and May 20 of the respective years [3] Company Overview - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges through innovative solutions [4] - The company employs over 95,000 people across more than 150 countries and offers technologies that treat 70 health conditions, including cardiac devices, surgical robotics, and patient monitoring systems [4] - Medtronic's mission is to alleviate pain, restore health, and extend life, emphasizing a commitment to delivering transformative healthcare solutions [4]

Core Insights - Medtronic's "Letter to My Mother" campaign aims to raise awareness about heart health among women, particularly focusing on the importance of discussing family health history and risk factors [4][13] - A survey conducted by Medtronic reveals a significant gap in awareness and discussions about heart health among women aged 30-50, despite cardiovascular disease being the leading cause of death for women in the U.S. [1][3] Survey Findings - Nearly half of the women (45%) are more likely to discuss sensitive topics like politics or money with their mothers than family heart health history, despite hereditary risks [2] - Over half (56%) of women have never discussed heart health with their mothers or family members, and only one-third (35%) of those with a family history of heart disease have consulted their doctors about their heart risk [7][8] - 53% of women worry that their aging mothers may ignore symptoms of heart disease, yet only 44% have actually talked about heart health with them [7][8] Health Disparities - Women are 35% less likely than men to receive treatment for heart valve failure, and they account for 52% of deaths caused by high blood pressure [3] - Heart disease disproportionately affects women of color, with 43% of Hispanic women and 59% of Black women experiencing some form of cardiovascular disease [3] Campaign Objectives - The campaign encourages women to prioritize heart health by initiating conversations about family history and risk factors [4][13] - Medtronic aims to close the awareness gap regarding heart disease, particularly focusing on high blood pressure and heart valve failure [4][13] Company Commitment - Medtronic is dedicated to improving health outcomes for women through personalized, evidence-based healthcare solutions [5] - The company is actively promoting awareness and advocacy for women's heart health, as evidenced by their partnership with WomenHeart [12]

Core Points - Medtronic plc's board of directors approved a cash dividend of $0.70 per ordinary share for the fourth quarter of fiscal year 2025, consistent with a previous dividend increase announced in May 2024 [1] - Medtronic has a strong history of dividend payments, having increased its annual dividend for 47 consecutive years, and is part of the S&P 500 Dividend Aristocrats index [1] - The dividend will be payable on April 11, 2025, to shareholders of record as of March 28, 2025 [1] Company Overview - Medtronic, headquartered in Galway, Ireland, is a leading global healthcare technology company focused on addressing significant health challenges through innovative solutions [2] - The company's mission is to alleviate pain, restore health, and extend life, supported by a global workforce of over 95,000 employees across more than 150 countries [2] - Medtronic's technologies and therapies address 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems [2]